Molecular alterations of driver genes in non-small cell lung cancer – from diagnostics to targeted therapy
Anna Grodzka, Agnieszka Knopik-Skrocka, Katarzyna Kowalska, Paweł Kurzawa, Monika Krzyżaniak, Katarzyna Stencel, Maciej Bryl
Abstract
are recognized. The frequency of some of those changes is different depending on race, and between smokers and non-smokers. The molecular diagnostics of NSCLC using modern methods, like next-generation sequencing, is essential in estimating targeted, personalized therapy. In recent years, a breakthrough in understanding the importance of molecular studies for the precise treatment of NSCLC has been observed. Many new drugs were approved, including tyrosine kinase and immune checkpoint inhibitors. Clinical trials testing novel molecules like miRNAs and trials with CAR-T cells (chimeric antigen receptor - T cells) dedicated to NSCLC patients are ongoing.